JAMA - J Am Med Assoc 315(1):3646
Endothelium-targeted deletion of microRNA-15a/16-1 promotes poststroke angiogenesis and improves long-term neurological recovery
Establishing the MC4R-centric nature of melanocortin-driven anorexia
Glatter: In practice, many patients labeled non-responders to GLP-1 therapy are experiencing incomplete dosing, early discontinuation because of gastrointestinal side effects, insufficient treatment duration, or competing metabolic drivers such as severe insulin resistance, sleep disruption, sarcopenia, or medication-associated weight gain
Ozempic is FDA-approved for: Controlling blood sugar in adults with type 2 diabetes Reducing the risk of serious heart problems, like heart attack, stroke, and death, in adults with type 2 diabetes and heart disease Reducing the risk of worsening kidney disease and cardiovascular deaths in adults with type 2 diabetes and chronic kidney disease
The bottom line GLP-1 drugs are not a replacement for insulin, and they are not officially approved for T1D (outside of the new 2026 ADA recommendation for T1D with obesity)
